Furthermore, RUNX3 is an important mediator during the development of both CD4+ and CD8+ cytotoxic T-lymphocytes (CTL), and is thus likely pivotal in the development of anti-tumor immunity [24]. The gene discussed is CD4; the disease is neoplasm.